917,925 Shares in Teleflex Incorporated $TFX Purchased by Abrams Bison Investments LLC

Abrams Bison Investments LLC bought a new position in shares of Teleflex Incorporated (NYSE:TFX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 917,925 shares of the medical technology company’s stock, valued at approximately $112,317,000. Teleflex comprises 8.8% of Abrams Bison Investments LLC’s portfolio, making the stock its 4th largest holding. Abrams Bison Investments LLC owned about 2.08% of Teleflex at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB lifted its holdings in Teleflex by 57.9% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Teleflex by 248.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock worth $34,000 after purchasing an additional 199 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Teleflex during the third quarter worth about $35,000. Quent Capital LLC purchased a new stake in shares of Teleflex during the third quarter worth about $38,000. Finally, Cullen Frost Bankers Inc. raised its position in shares of Teleflex by 496.7% in the third quarter. Cullen Frost Bankers Inc. now owns 358 shares of the medical technology company’s stock valued at $44,000 after buying an additional 298 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Price Performance

Shares of Teleflex stock opened at $107.29 on Friday. Teleflex Incorporated has a twelve month low of $100.18 and a twelve month high of $143.32. The stock has a market capitalization of $4.74 billion, a P/E ratio of -5.22, a PEG ratio of 0.67 and a beta of 0.87. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. The business’s fifty day moving average price is $109.80 and its 200 day moving average price is $118.04.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 EPS for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). The firm had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $912.57 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The business’s revenue for the quarter was down 28.5% compared to the same quarter last year. During the same quarter last year, the business earned $3.89 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, March 6th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend is Friday, March 6th. Teleflex’s dividend payout ratio is -6.62%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen lowered Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Wells Fargo & Company upped their target price on Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Needham & Company LLC increased their target price on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Truist Financial raised their price target on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research note on Thursday, December 18th. Finally, Zacks Research cut Teleflex from a “hold” rating to a “strong sell” rating in a report on Monday, March 2nd. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Teleflex presently has a consensus rating of “Hold” and an average target price of $140.83.

Teleflex Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.